Immunotherapy in Non-small Cell Lung Cancer: a Review
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.48729/pjctvs.371 |
Resumo: | Immunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy are not fully understood, and ongoing research aims to overcome these challenges. In the early-stage setting, neoadjuvant and adjuvant trials are investigating the efficacy of ICIs in combination with chemotherapy, with interesting results. Additionally, in the metastatic landscape of NSCLC the therapeutic options multiplied in recent years. The use of immunotherapy in NSCLC holds great promise, and future studies may provide more effective therapies and biomarkers for personalized treatment approaches. |
id |
RCAP_9578b0443985085a7d7b75cb2409883f |
---|---|
oai_identifier_str |
oai:oai.pjctvs.com:article/371 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Immunotherapy in Non-small Cell Lung Cancer: a ReviewimmunotherapyNSCLCtreatmentlung cancerimmune checkpoint inhibitorsImmunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy are not fully understood, and ongoing research aims to overcome these challenges. In the early-stage setting, neoadjuvant and adjuvant trials are investigating the efficacy of ICIs in combination with chemotherapy, with interesting results. Additionally, in the metastatic landscape of NSCLC the therapeutic options multiplied in recent years. The use of immunotherapy in NSCLC holds great promise, and future studies may provide more effective therapies and biomarkers for personalized treatment approaches.SOCIEDADE PORTUGUESA DE CIRURGIA CARDIO-TORÁCICA E VASCULAR2023-10-11info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.48729/pjctvs.371https://doi.org/10.48729/pjctvs.371Portuguese Journal of Cardiac Thoracic and Vascular Surgery; Vol. 30 No. 3 (2023): Jul-Sep; 55-652184-9927reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://pjctvs.com/index.php/journal/article/view/371https://pjctvs.com/index.php/journal/article/view/371/333Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgeryinfo:eu-repo/semantics/openAccessSequeira, TelmaAlmodovar, M. Teresa2023-10-21T04:52:54Zoai:oai.pjctvs.com:article/371Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:35:37.383835Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Immunotherapy in Non-small Cell Lung Cancer: a Review |
title |
Immunotherapy in Non-small Cell Lung Cancer: a Review |
spellingShingle |
Immunotherapy in Non-small Cell Lung Cancer: a Review Sequeira, Telma immunotherapy NSCLC treatment lung cancer immune checkpoint inhibitors |
title_short |
Immunotherapy in Non-small Cell Lung Cancer: a Review |
title_full |
Immunotherapy in Non-small Cell Lung Cancer: a Review |
title_fullStr |
Immunotherapy in Non-small Cell Lung Cancer: a Review |
title_full_unstemmed |
Immunotherapy in Non-small Cell Lung Cancer: a Review |
title_sort |
Immunotherapy in Non-small Cell Lung Cancer: a Review |
author |
Sequeira, Telma |
author_facet |
Sequeira, Telma Almodovar, M. Teresa |
author_role |
author |
author2 |
Almodovar, M. Teresa |
author2_role |
author |
dc.contributor.author.fl_str_mv |
Sequeira, Telma Almodovar, M. Teresa |
dc.subject.por.fl_str_mv |
immunotherapy NSCLC treatment lung cancer immune checkpoint inhibitors |
topic |
immunotherapy NSCLC treatment lung cancer immune checkpoint inhibitors |
description |
Immunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy are not fully understood, and ongoing research aims to overcome these challenges. In the early-stage setting, neoadjuvant and adjuvant trials are investigating the efficacy of ICIs in combination with chemotherapy, with interesting results. Additionally, in the metastatic landscape of NSCLC the therapeutic options multiplied in recent years. The use of immunotherapy in NSCLC holds great promise, and future studies may provide more effective therapies and biomarkers for personalized treatment approaches. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-10-11 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.48729/pjctvs.371 https://doi.org/10.48729/pjctvs.371 |
url |
https://doi.org/10.48729/pjctvs.371 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://pjctvs.com/index.php/journal/article/view/371 https://pjctvs.com/index.php/journal/article/view/371/333 |
dc.rights.driver.fl_str_mv |
Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgery info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgery |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SOCIEDADE PORTUGUESA DE CIRURGIA CARDIO-TORÁCICA E VASCULAR |
publisher.none.fl_str_mv |
SOCIEDADE PORTUGUESA DE CIRURGIA CARDIO-TORÁCICA E VASCULAR |
dc.source.none.fl_str_mv |
Portuguese Journal of Cardiac Thoracic and Vascular Surgery; Vol. 30 No. 3 (2023): Jul-Sep; 55-65 2184-9927 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133619221954560 |